Il partenariato transnazionale dei Progetti UNIPHARMA-GRADUATES si √® progressivamente ampliato nel corso degli anni e comprende attualmente¬†circa 35 centri di ricerca, pubblici e privati, all'avanguardia nel settore chimico, farmaceutico, biotecnologico, in 6 paesi europei.
Ogni anno i centri ospitanti propongono circa 150 programmi di lavoro fra i quali i candidati selezionati possono scegliere il progetto pi√Ļ adeguato al proprio percorso formativo e ai propri obiettivi.
Qui di seguito potete trovare una descrizione sintetica dei Centri di ricerca attualmente partner del programma, ordinati per paese e citt√†.
N.B.:¬†il partenariato √® soggetto a variazioni da un progetto all'altro. La lista che segue √® da considerarsi quindi indicativa.
L'elenco definitivo con le informazioni dettagliate sui centri e sui progetti offerti vengono fornite, per ogni progetto, solo ai candidati che risultano vincitori del bando.
Cambridge - The Babraham Institute (Babraham Research Campus)
Cambridge - Innova Biosciences Ltd (Babraham Research Campus)
Cambridge - Kymab Ltd (Babraham Research Campus)
The focus of our research group is on synthetic organic chemistry. Our main research topics are:
‚ÄĘ Synthesis of biologically active natural products and their analogues: examples are the synthesis of Peloruside A (a promising antitumor compound from marine origin, acting as a tubulin depolymerization inhibitor with an activity similar to that of taxol) and analogues of Lipid II (the building block for the biosynthesis of the bacterial cell wall) as transglycosylase inhibitors with potential antibiotic activity.
‚ÄĘ Design and synthesis of novel heterocyclic ‚Äúprivileged‚ÄĚ scaffolds for drug design via solid phase synthesis.
‚ÄĘ Synthesis of novel chiral ligands for asymmetric transition metal catalysis for the synthesis of enantiomerically pure building blocks.
The primary aim of the laboratory is to perform basic and applied research in the area of MICROWAVE CHEMISTRY (Microwave-Assisted Organic Synthesis ‚Äď MAOS). The application of this technique is evaluated in different areas of organic synthesis.
- Dedicated mono- and multimode microwave instruments
- NMR: 300, 400 and 600 MHz (for H1-NMR)
- MS, HRMS
(Inter)national collaborations with different groups.
The Institute of Protein Biology and Chemistry (IBCP) is an excellence mixed research unit (UMR 5086) jointly administered by the CNRS and by University of Lyon I. It is located in Lyon (France) in the Gerland area, at the confluence of Rh√īne and Sa√īne rivers. It is one of the ten research units constituting the Federated Research Institute (IFR 128) "Biosciences Lyon-Gerland".
The current building dates from 1992 (phase 1), and was extended in 1997 (phase 2, North West wing) and again in 2003 (phase 3, two additional floors), making a current surface area of 4500 m2 distributed over 5 floors.
The general aim of the research is the study of proteins in their biological context. The approaches used include integrative cellular (cell culture, various types of microscopies) and molecular techniques, at both experimental (genetic engineering, biochemistry, biophysics, crystallography and nuclear magnetic resonance) and theoretical (structural bioinformatics) levels.
The 13 research groups are spead over 3 scientific departments of equivalent sizes: Molecular biostructures, Membranes, signalling & transport, and Matrix biology & tissue engineering.
Altogether, it includes about 170 people (researchers, university academic staff, technicians, administrative staff, postdoctoral researchers and PhD students), representing 9 nationalities, of which half have tenured positions. The IBCP houses the Lyon-Gerland site of the Rhone-Alpes Bioinformatics Centre (PRABI) and various technical platforms.
The Institute is equipped with all major facilities at both molecular and cellular levels. Additional, more specific, equipments are available in close proximity, within the IFR 128. It is considered as one of the best European research centers dedicated to Protein Science.
ESPCI ParisTech is a major institution of higher education (a French "Grande √Čcole d‚Äôing√©nieurs"), an internationally renowned research center, and a fertile ground of innovation for industry. The School‚Äôs teaching faculty and researchers are building tomorrow‚Äôs knowledge base, publishing an article a day in top international scientific journals; inventing the industry of the future, filing for a patent every single week. ESPCI ParisTech is home to 17 advanced research laboratories at the frontiers of scientific knowledge and experimental know-how, covering areas ranging from polymers to telecommunications, from nanobiophysics to organic synthesis, from environmental science to biomedical imaging, from neurobiology to microfluidics, from soft matter to quantum physics, and from colloids to industrial prototyping.
The group has recently moved from the Institut de Science et d'Ing√©nierie Supramol√©culaires (ISIS), Strasbourg, France. The new Laboratory of Biochemistry (LBC) was created in September 2012 at the Ecole Sup√©rieure de Physique Chimie Industrielles de la Ville de Paris (ESPCI ParisTech), and is directed by Prof. Andrew Griffiths. We are also part of CNRS (Centre National de la Recherche Scientifique). The research activities of LBC are based around droplet-based microfluidics, a powerful new ultrahigh throughput system in which reaction volumes can be minaturized by up to a million-fold compared to conventional assays in microtitre plates. This opens up exciting prospects for the development of extremely innovative systems with many applications in the Life Sciences.
The team is highly multidisciplinary; our goal is to create and to improve microfluidic set-ups and develop a range of different bioassays on molecules, cells, bacteria and virus-like particles. Our research activity is related to high throughput screening and evolutionary biology, to address challenges in drug discovery, industrial biochemistry, diagnostics and therapeutics. The laboratory is fully equipped with molecular and cell biology labs, tissue culture facilities, clean rooms for microfluidic device fabrication by soft lithography and several microfluidic stations comprising syringe pumps, multicolor optical detection systems, and data acquisition and control systems.
The Gif Research Center is located 25 km away from Paris, in the ‚ÄúVall√©e de Chevreuse‚ÄĚ, at the Gif-sur-Yvette campus in a 65-hectare domain with an 18th century park. Part of the ‚ÄúParis-Saclay Campus‚ÄĚ, the Center counts more than 900 scientists (290 researchers, 50 professors and lecturers, 250 engineers and technicians, 150 post-doctoral fellows) which inhabit 35.000 m2 of laboratory spaces (11 research units and 3 facilities). The French government has budgeted in the last five years over $ 25 billion of euros to the Paris-Saclay Campus to create the French version of Cambridge. The project, spanning ten years, is to assemble the largest campus in Europe, the technology Latin Square of the 21st century, reaping the benefits of ‚Äúthe cafeteria effect‚ÄĚ of Silicon Valley. The plan for Paris-Saclay is to build a campus to the south of Paris, just a few miles from Notre Dame and the Eiffel Tower that can compete with the most distinguished centers of global research and attract the best students and top researchers in the world. The Gif Research Center holds already 200 doctoral students from over 30 different countries in association with 17 Graduate schools. The associated University Paris-Sud (Paris XI) is the first French University in the Shangha√ģ classification (evaluating the performance in Academic Ranking of the World Universities) being in the TOP of the first 40th Universities in the world. The instrumentation and research teams of the Center are regularly involved in various educational and training programs for interns at every stage of their research, for doctoral and post-doctoral students and for private companies (2000 hours of teaching by researchers, 60 Ph.D. theses defended per year).
The campus represents an exceptional multidisciplinary and thought-provoking environment (more than 400 publications per year, 17 technology platforms for open collaborations/services, 25 ongoing European contracts, hundreds of projects financed by the French National Research Agency, 55 other ongoing contracts), where chemists, biologists (structuralists, cell biologists, physiologists, geneticists, bioinformaticians and neuro-informaticians) and physicists collaborate to investigate the major human, animal, plant and microbial functions and their alterations in various pathologies. Research themes at the Center includes: Chemistry, and chemistry/biology interface; Structural biology and molecular mechanisms; Molecular complexes and cell functions; Genetics and genomics; Morphogenesis, organogenesis and the development of organisms; Physiology of organs and organisms; Neurosciences; Neuroinformatics;
Multiscale analysis and integrative biology; Evolution, biodiversity and interactions with the environment; Molecular basis of pathologies and therapeutic innovations.
Internationally renowned tumour and biology institute, which includes a large number of disciplines, for example cell biology, immunology, epigenetics, genomics, physics, chemistry, bioinformatics. Great research environment, with many interactions at the interface between several disciplines. International student and post-doctoral programs.
State-of-the-art technological platforms: genomics, proteomics, flow cytometry, confocal and 2-photon microscopy, electron microscopy, intra-vital microscopy, animal facility.
All lab meetings and journal clubs are in English, which is the official language for researchers.
The Institut Curie has two sites, one in the center of Paris and one in Orsay, a southern suburb of Paris, easily reached by train.
The Institut de Recherches SERVIER is one of the 2 research centres of the private French Pharma Laboratoires SERVIER. Altogether, the centres comprise more than 500 searchers: chemists and biologists/pharmacologists. The goal of the centres is to provide the company with research programs aiming at the discovery of compounds active on major sicknesses in the domains of Oncology, Cardiology, Neurosciences, Rheumatology and Metabolism/Obesity.
Within our multidisciplinary research organization, the Medicinal Chemistry department aims at the design and synthesis of innovative biologically active compounds that will lead to effective and safe human therapeutics.
Since its creation in 1887, the Institut Pasteur has become a symbol of science and french culture. For 120 years, our foundation has been contributing to the prevention and treatment of infectious diseases through research, teaching and public health initiatives. Thousands of researchers who have been trained or are working at Institut Pasteur share the values which form the very core of the Pasteurian community: an original scientific approach, an ongoing preoccupation with applying research to public health needs, professional ethics, a desire to care for people regardless of their background or nationality, and an outward-looking attitude, sharing knowledge and expertise with the international community. The campus in Paris hosts almost 2800 individuals. Research priority is given to fight infectious diseases, such as viral, bacterial, and parasitic diseases, as well as other diseases such as certain types of cancer, genetic diseases, neurodegenerative diseases, and allergy. Over 800 trainees from 60 different countries come to perfect their skills in the Institute‚Äôs laboratories.
Research at the iRCM is focused on the study of the effects of ionising radiation and of other environmental stresses on somatic and germinal stem cells, their genetic stability and their transformation.
Orientations involve both fundamental and applied research, extending the results on the effects of radiation to stem cells and paving the way for a range of technological innovations.
The core mission of the IRCM is to deploy research programmes designed to:
analyse the fundamental mechanisms involved in DNA damage repair and cell survival,
analyse the effects of radiation on both adult and foetal somatic stem cells,
drive the research needed in order to understand how the late effects of radiation therapy are induced and appear,
analyse the mechanisms underlying the formation and transmission of the damage caused by (weak or strong doses of) ionising radiation and the consequences involved
The iRCM employs around 170 permanent research staff working in 4 departments, Genetic Instability, Repair and Recombination Research, Stems Cells and Radiation, Radiation Biology Research and Technical Innovation, and Radiation Biology and Oncology. CEA/CNRS, CEA/Inserm, CEA/INRA and CEA/University joint research units are involved in each department.
Orientations involve both fundamental and applied research, extending the results on the effects of radiation to stem cells and paving the way for a range of technological innovations.
Paris Descartes University (Paris 5) is one of the main Paris Universities with two major fields of research: health and social sciences. The laboratories of ¬†the Faculty of Pharmacy are attached to the federative Institute for ‚ÄúMedical agents, Toxicology, Chemistry and Environment‚ÄĚ (MTCE) including 18 laboratories recognized by the French research organizations (4 CNRS, 6 INSERM, 2 Mixed CNRS-INSERM, 5 UNIVERSITY) and working at the interface of biology and chemistry. They are located in full center of Paris.
Work programmes for the UPG candidates 2013 were proposed by:
-¬†IMTCE (Institut M√©dicament Toxicologie Chimie Environnement) - Team Pharmacology of cerebral circulation(http://recherche.parisdescartes.fr/EA4475)
- CNRS UMR 8638 ¬†- Laboratory of ‚ÄúPeptides and Peptidomimetics against angiogenesis‚ÄĚ¬†(http://www.ssmip.cnrs.fr/)
The laboratory is part of the UMR CNRS 8638, whose facilities include UV, FTIR, NMR and mass spectrometers, polarimeter, GC, MPLC, and HPLC devices. The team of Pr. Michel Vidal employs specialists in organic synthesis and peptide chemistry and biochemistry, including 5 academic staff members and a PhD student.
The main research activities of our team are related to the discovery and the preparation of novel biologically active anti-angiogenic and broadly anti-cancer compounds. We study more specifically protein/protein interactions, in particular the VEGF-VEGFR1 (Vascular Endothelial Growth Factor Receptor 1) interaction. The biologically active molecules developed in the laboratory include both peptides and organic heterocyclic molecules.
-¬†Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, CNRS UMR 8601(http://www.biomedicale.univ-paris5.fr)
Our laboratory is attached to the IMTCE institute of University Paris Descartes. The site includes 10 laboratories recognized by the French research organizations. This research center includes two poles, ‚Äúpharmacology, toxicology, cancerology‚ÄĚ and ‚Äúneurosciences‚ÄĚ and our laboratory is attached to the first of these two poles. We are located in full center of Paris (district of Saint Germain des Pr√©s), at the Faculty of Medicine (Biomedical center) Paris 5. The laboratory of ‚ÄúChimie et Biochimie Pharmacologiques et Toxicologiques‚ÄĚ comprises 80 people including 60 statutory members, and PhD students and post-doctoral fellows.The objectives of our group are to characterize and validate new protein targets involved in the deregulations of cell signaling in association with pathologies and more particularly oncology. ¬†A second phase consists in the development of inhibitors of these proteins with a pharmacological aim to test their effects in vitro and on cellular models. ¬†Our multi-field approach associates the techniques of molecular and cellular biology of the targets, the chemistry and molecular modeling and the physicochemical and enzymatic tests of the pharmacological agents. ¬†Our targets are located in the ways of transduction induced by the tyrosine kinase receptors (Grb2, RasGAP, STAT3) and in the cellular cycle (CDC25, Cdk) or are kinases like focal adhesion kinase FAK and the VEGF receptor.
- INSERM UMR-S 1124 - Pharmacology, Toxicology, Cell Signaling (http://www.biomedicale.parisdescartes.fr)
The scientific environment at the Faculty of Fundamental and Biomedical Sciences (Paris Descartes University) in the fields of neuroscience and pharmacology-toxicology is very rich since several laboratories (CNRS, INSEMR‚Ä¶) are hosted and the trainees will take advantage of different scientific seminars where internationally known scientists present the state of art of their respective research topics. Besides, different technical common facilities are available (animal facility, Q PCR and imaging facilities, etc.).
The INSERM UMR-S¬†1124 is located at the Biomedical Faculty and include different teams (total > 50 members) working at molecular, cellular and in vivo levels, including animal models and also at clinical level, working on healthy subjects and also during the pathological conditions regarding the sensorimotor functions.
- Laboratory of Pharmacognosy and vegetal sciences, UMR CNRS 8638
The laboratory of ‚ÄúPharmacognosy and vegetal sciences‚ÄĚ of the Faculty of Pharmacy of the Universit√© Paris Descartes is part of the UMR CNRS 8638, whose facilities include UV, FTIR, NMR and mass spectrometers, polarimeter, GC, MPLC, and HPLC devices. It employs specialists in natural products chemistry, including 10 academic staff members, 10 PhD students, 2 postgraduate students, 1 engineer, and 3 technicians.
The main research activities of the Department of Pharmacognosy are related for one part to the discovery of novel biologically active natural compounds: isolation, structure determination and synthesis, for the other one on the conception of structural analogues of bioactive compounds in order to identify novel drug candidates based on natural models.
The major activity deals with antitumour and antiinfective leads starting from plants selected either for their use in traditional medicine or on the basis of chemotaxonomic considerations. Major recent achievements in order to establish structure activity relationships and to determine the mechanism of action of active compounds at both molecular and cellular levels include the development of a novel anticancer agent (S-23906), based on the structure of the natural acridone alkaloid acronycine and the identification of a new class of antitubercular agents (benzofurobenzopyrans) based on the structure of natural phytoalexins from higher plants and lichen secondary metabolites.
The laboratory is also involved in an emerging approach targeting the established tumour vasculature by the synthesis of vascular disrupting agents leading to hemorrhagic necrosis within tumours.
The last activity developed, is the preparation of original scaffolds from non commercially available chiral natural products, for further use in parallel and combinatorial chemistry directed toward the discovery of new antibiotics and antitumour agents.
The University Paris 13 (UP13) or University Paris-North is one of the thirteen universities in Paris. It is divided in three campus localized at Villetaneuse, Bobigny and Saint-Denis. The UP13 is a mayor multidisciplinary centre for education and research at the north of Paris with around 22000 students registered in 2008.
The university campus at Bobigny is the site for the L√©onard de Vinci Medical training and research unit (UFR) of Health, Medicine and Human Biology (SMBH) and the University Institute of technology of Bobigny.
The UFR SMBH L√©onard de Vinci is the first establishment of higher education in France with an experimental vocation in the fields of health and medicine. It offers training programs in 4 different disciplines: 1) medicine, 2) life sciences, 3) health and social sciences and 4) physical activity and sporting techniques and sciences.
The campus is also an important research site as it shelters 18 different CNRS and INSERM research units where medical doctors, scientific researchers and university professors work together. It also holds important links with other french and foreign universities, international organizations and public and private health institutions with the permanent objective of bringing together University and Health entities.
The Center of Pathophysiology of Toulouse-Purpan (CPTP) is a publicly-funded research Centre, co-sponsored by the French National Institute of Health and Medical Research (INSERM), the National Institute for Scientific Research (CNRS) and the University of Toulouse. ¬†The Center is located within Toulouse, a dynamic and student-friendly city in the Southwest of France, 1 hour away from Paris by plane shuttle. ¬†Of note, Toulouse has the 2nd largest student population in France.
The CPTP is composed of around 220 people and 15 independent research teams covering various aspects of immunology, inflammation and infection. ¬†The quality of the CPTP is reflected by the high impact of the recent publication record by the different team members (e.g. Journal of Experimental Medicine, Nature, Nature immunology, Journal of Clinical Investigation, Science Translational Medicine, PLoS Pathogens). ¬†The CPTP has a major expertise in lymphocyte biology, host-pathogen interactions, immune responses to infection and autoimmunity.
The CPTP provides an excellent environment to perform ‚Äústate of the art‚ÄĚ immunological research on infectious diseases. ¬†All scientific and technological facilities are integrated into a regional network of platforms (http://www.genotoul.fr/) and all facilities necessary for the implementation of the proposed project are available on-site (e.g. flow cytometry, photonic imaging, histopathology, animal facility).
Research teams at the CPTP host international trainees of various nationalities (Italian, Dutch, Austrian, Portugese, Spanish, Brazilian, etc), ranging from undergraduate students to postdocs. ¬†External seminars as well as most lab meetings are held in English.
The Max Delbr√ľck Center for Molecular Medicine (MDC) is one of Germany‚Äôs top research institutions, covering a diverse interdisciplinary spectrum of basic and clinically relevant biomedical sciences. With regard to the quality of published papers, the MDC is ranked as the best German research institution (‚ÄúExcellence Rate Report‚ÄĚ, SCImago Research Group, 2011) and is 14th among the top 20 life science institutes worldwide in the field of molecular biology/genetics (Thomson Reuters, 2010). The MDC is a member of the Helmholtz Association, Germany‚Äôs largest scientific research organization.
The MDC‚Äôs scientific program is centered on four main research areas: Cardiovascular and Metabolic Diseases,
Cancer, Diseases of the Nervous System, Medical Systems Biology
¬∑ 75 basic science and clinical research groups
¬∑ more than 1,500 staff from around 60 countries, including more than 200 post-docs, and around 350 PhD students
¬∑ annual budget of approximately ‚ā¨90 million
¬∑ 7 EMBO members, 2 EMBO YIP awards; 5 starting and 4 advanced ERC grants
¬∑ 3 Leibniz prize-winners, 6 German Cancer Award laureates.
The MDC Graduate School (www.mdc-berlin.de/phd) provides exceptional research opportunities and in-depth interdisciplinary training in the field of molecular medicine as the foundation of modern medicine. Research areas include cancer biology, immunology, cardiovascular research, metabolic research, developmental biology, medical systems biology, bioinformatics, structural biology and molecular neurobiology. A comprehensive and structured training program in a unique translational research environment with access to state-of the-art technology platforms is complemented by various career development courses. There are currently five specialized PhD programs:
¬∑ MDC - NYU PhD Exchange Program in Medical Systems Biology
¬∑ SignGene - German-Israeli Helmholtz Research School 'Frontiers in Cell Signaling and Gene Regulation' (with the HU Berlin, Charit√©-Universit√§tsmedizin Berlin, Technion-Israel Institute of Technology and Hebrew University of Jerusalem)
¬∑ TransCard - International Helmholtz Research School 'Translational Cardiovascular & Metabolic Medicine' (in partnership with the Hubrecht Laboratory (Utrecht, Netherlands) and the University of Arizona (Tucson AZ, USA)
¬∑ MolNeuro - International Helmholtz Research School 'Molecular Neurobiology'
¬∑ MyoGrad - International Research Training Group for Myology (with the Charit√©-Universit√§tsmedizin Berlin, FU Berlin and the University Pierre et Marie Curie in Paris).
The MDC is located in Berlin, one of the most vibrant and international cities in Europe. Exceedingly open and tolerant, Berlin‚Äôs tremendous creative spirit drives both culture and science. At the same time Berlin is one of the most affordable capitals in Europe.
Heidelberg University has a very well established international neuroscience research programme. The interdisciplinary Centre for Organismal Studies (COS, http://www.cos.uni-heidelberg.de/) and the Centre for Neurosciences (IZN,http://www.izn.uni-heidelberg.de/) cover this framework. IZN encompasses all research activities in the neurosciences field, providing wide opportunities for scientific exchange at all levels. Research at COS is strongly rooted in neuroscience, from neural stem cells to axon guidance and processing of sensory information. As a junior group leader, I am member of both COS and the IZN. My research group lies in the department of Dep. of Developmental Biology/Physiology of COS. My main goal is to understand how neuron subtypes specification and neural circuits formation are regulated in the developing vertebrate retina. We watch how neuronal stem cells divide and differentiate in vivo by performing extensive cellular resolution time-lapse imaging and concurrent visualization of expression and function of key cell fate determinants (see University Press, http://www.uni-heidelberg.de/presse/news2012/pm20121203_nervenzellen_en.html).
We are very well equipped with a big fish facility and excellent microscopy resources for in vivo imaging as well as software needed for image acquisition, processing and analysis. At present, my group is composed of three PhD students and one master thesis student. We are very well integrated with the laboratory of Jochen Wittbrodt (director of the department), with which we have established open collaborative interactions and share expertise and genetic tools.
The Karlsruhe Institute of Technology (KIT) has been founded in October 2009. Being a merger of Forschungszentrum Karlsruhe GmbH and Universit√§t Karlsruhe (TH), KIT is a university if the State of Baden-W√ľrttemberg and a national research center of the Helmholtz Association. It focuses on a knowledge triangle that links the tasks of research, teaching, and innovation.
Research at the Institute of Toxicology and Genetics (ITG) aims to elucidate molecular and cellular interactions at functional interfaces. One focus is the identification of key biological molecules that play major roles in:
¬∑ Cellular signalling
¬∑ Cell differentiation and proliferation
¬∑ Embryonic development in fish
¬∑ Pathophysiology of disease
The Helmholtz Centre for Environmental Research - UFZ, Germany, was established in 1991 as the first and only centre in the Helmholtz Association of National Research Centres to be exclusively devoted to environmental research in a great variety of fields. It currently employs around 1000 people. Founded in response to the severe pollution prevailing in Central Germany, the UFZ has become a world-wide acknowledged centre of expertise in the remediation and re-naturation of contaminated landscapes, as well as the preservation of biodiversity and natural landscapes. The UFZ has the capacity, resources and experience to participate in this project. Since its foundation in 1991, the UFZ has participated in more than 150 EC funded projects. In Framework six, UFZ is or was involved in 48 projects co-ordinating three Integrated Projects, two STREPs, two ESTs, one RTN, one SFC, and five TOKs. At present, the UFZ is participating in or in grant agreement negotiations for 45 Cooperative Projects within FP7, eight of them are coordinated by UFZ. Additionally, the UFZ is hosting two ERC grants, one starting grant and one advanced grant, eleven Marie Curie Individuals Fellowships and is coordinating three ITNs.
Plant Research International (PRI) is one of the strategic research institutes of Wageningen University and Research Centre (WUR). WUR combines fundamental and applied research with innovative education in the areas of food, agrotechnology, production systems, nature and the environment. About 5500 employees are committed to translating technological knowledge into study programmes and practical applications. All plant scientific groups including PRI are situated in a new building on the campus of WUR (see picture below).
PRI is a non-profit organisation that is active in all fields of plant related sciences, from molecule to agrosystems, and is the biggest Dutch research institute in the field of plant biotechnology. The total staff of about 450 persons includes members from 30 different nationalities. Some 130 researchers and trainees from abroad are playing an important role in our organisation. As all Dutch employees are at least bi-lingual, all internal scientific meetings are conducted in English. The research described below in the WORK programs will take place within the Business unit (BU) Bioscience. The topics of this BU include the genomics, proteomics, and metabolomics fields.
The CRG is located in the wonderful city of Barcelona; it is part of the Biomedical Research Park of Barcelona (PRBB) and is connected to the Hospital del Mar. The PRBB groups together different institutions, including the Experimental and Health Sciences Department of the Pompeu Fabra University, the Municipal Institute of Medical Research, the Centre of Regenerative Medicine in Barcelona, and the Centre for Research in Environmental Epidemiology, creating a critical mass of biomedical research.
The Centre for Genomic Regulation (CRG) is a centre of innovation for basic research, created in December 2000 and officially inaugurated in 2002. It is a non-profit foundation funded by the Catalan Government through Economy and Knowledge Department and the Health Department, the Spanish Ministry of Economy and Competitiveness, and includes participation from the Pompeu Fabra University (UPF).
The mission of the CRG is to discover and advance knowledge for the benefit of society, public health and economic prosperity.
The CRG believes that the medicine of the future depends on the groundbreaking science of today. This requires an interdisciplinary scientific team focused on understanding the complexity of life from the genome to the cell to a whole organism and its interaction with the environment, offering an integrated view of genetic diseases.
Its main goals are: a) to be a world leading centre in biomedical science; b) to communicate and establish a bilateral dialogue with society; c) to provide advanced training for the next generation of scientists; and d) to translate new scientific knowledge into benefits for health and value for society.
Presently the CRG has 4 programmes:
¬∑ Bioinformatics and Genomics,
¬∑ Cell and Developmental Biology,
¬∑ Gene Regulation, Stem Cells and Cancer
¬∑ Systems Biology, ¬†including the EMBL/CRG Systems Biology Research Unit
Each program consists of a different number of independent research groups.
Group leaders at the CRG are recruited internationally and receive support from the centre to set up and run their groups. An external Scientific Advisory Board periodically evaluates all of the principal investigators. The results of these evaluations determine their future at the CRG, no matter whether they have open-ended or fixed-term contracts. This ensures high standards of excellence in science as well as mobility and renewal of the workforce.
CORE FACILITIES: The CRG offers state-of-the-art core facilities, access to the modern animal house of the PRBB and the Transgenic Mouse Facility at the EMBL in Monterotondo.
¬∑ Genomics: Genotyping, Microarrays, Deep Sequencing
¬∑ Advanced Light Microscopy, super-resolution
¬∑ Biomolecular Screening & Protein Technologies
Overview of the training activities of the CRG
The CRG is devoted to excellence in training at all stages of careers in the life sciences: PI‚Äôs, postdocs PhD and undergraduate students and technicians.
The CRG hosts a well-known International PhD Programme that attracts young talents from all over the world. The programme is supported by internal and external funds and, since 2008, ‚ÄúLa Caixa‚ÄĚ PhD Fellowship Programme for selected biomedical institutes in Spain. To oversee the quality of the PhD Programme, the Graduate Committee, composed of faculty members and chaired by two scientists, was created in 2006. It is responsible for organising all issues related to the PhD students, in particular establishing the conditions for admission, follow-up of student‚Äôs progress and Master and PhD courses.
The International Postdoctoral Programme at the CRG currently hosts around 100 postdocs, 72% of them are non-Spanish. The postdoctoral community at the CRG was strengthened in 2010 with the support of a new grant obtained from the European Commission to create a new Postdoctoral Programme for high talented cross-disciplinary postdocs (INTERPOD). The Postdoctoral Committee was created also in 2010 to monitor the implementation of the INTERPOD programme and deal with postdoc-related issues. Efforts to increase the international mobility with leading institutions in biomedicine have led to an agreement with a top biomedical research institute in India, the National Center for Biological Sciences (NCBS) for the establishment of a joint NCBS-CRG Postdoctoral Fellowship Programme. The first call was launched in September 2012.
A new agreement in 2013 for a Mobility Programme has been reached with Novartis and the Wits University to host South-African PhD students/postdocs at the CRG for a period of 6 months.
The CRG offers integrated training covering training-through-research (scientific project under the supervision of the PI), hands-on and theoretical courses, regular conferences and seminars with top invited speakers and internal data and journal clubs, to empower fellows with new skills and competences. Training is also offered openly to the scientific community through the initiative Courses@CRG launched in 2012. We aim to make the courses@CRG a flagship training activity of the CRG, critical to incorporate the latest technologies and concepts in Europe and worldwide. Additionally, the CRG has a dedicated outreach programme to promote the new scientific vocations and offers also training courses for secondary school teachers. The recently established full-equipped Teaching and Training Labs, with the support from private sponsors, will be key to host the growing training activities of the CRG at all stages of careers from courses and workshops, activities for school children to master internships.
IRB Barcelona provides young scientists with the opportunity to do training and research in a unique and multidisciplinary scientific environment. The Institute has a well-established international PhD Fellowship programme hosting more than 135 students from around the world who are currently working toward their doctoral degrees. Admission is international and competitive over more than 300 applications from more than 25 countries are received each year. IRB Barcelona‚Äôs International PhD Programme is one of four across Spain to be selected by the ‚Äúla Caixa‚ÄĚ Foundation (a non-profit organization funded by the third largest financial organization in Spain) to receive special funding for up to 10 students per year for 4 years. In addition, the IRB Barcelona launches yearly the IRB Barcelona PhD fellowships. The objective of this call is to attract talented students by giving them an opportunity to start their doctoral studies at IRB Barcelona before national fellowship calls from funding organisations are announced. The institute also benefits from other regional, national, European and international PhD fellowship programmes. The candidates joining the institute by non-IRB Barcelona PhD calls are requested to have the approval by a selection committee. ¬†All the IRB Barcelona students receive close mentoring and have access to the wide variety of scientific training activities available. IRB Barcelona‚Äôs PhD students are highly pro-active, a reflection of this is that they have taken it upon themselves to form a committee to organize initiatives to support and enrich their daily research activities.
PhD mentoring system: Coordinated by the Chair of Graduate Training, the institute has designed and is continuously updating a system to complement the training of its PhD student community, with the ultimate goal to give them the opportunity to join the scientific elite.
This system includes:
‚ÄĘ Personalised Thesis Advisory Committee (TAC): three independent experts guide the student during his/her doctorate. The thesis director is not member of the TAC.
‚ÄĘ Introductory course.
‚ÄĘ Lab Rotations. Students perform two short stays in laboratories of the institute.
The PhD Programme is monitored by the PhD Committee, which aims to implement all the procedures related to the training of the IRB Barcelona predoctoral community. The PhD Committee includes one GL from each of the research programmes and is headed by the Chair of Graduate Training.
The PhD students are organized in the PhD Student Council, whose mission is to give feedback to both the Chair of Graduate Training, the PhD Committee, and the Directorate on any issues that may arise.
In addition, every two years the PhD student community organizes the International IRB PhD Student Symposium. The first and second editions, held in 2009 and 2011, were a success in number and quality of participants and speakers (two Nobel laureates). The third edition, ‚ÄúThe Clock of Life: Cellular and Molecular Processes of Development, Ageing and Disease‚ÄĚ will be held on 14-15 November 2013.
IRB Barcelona is located within the campus of the Barcelona Science Park, an institution in which first-class public research converges with the private sector in a stimulating scientific environment. The Institute seeks to promote multidisciplinary research of excellence at the interface between biology, chemistry and medicine, to foster collaborations with local organisations and international research institutes, and to provide high-level training in the biomedical sciences to staff, students and visitors.
Research at IRB Barcelona has at present 23 group leaders performing independent research and is organized into five programmes, selected following criteria of scientific opportunity. These five programmes, which are complementary and synergistic with biomedical clinical fields, are: Cell and Developmental Biology, Oncology, Molecular Medicine, Chemistry and Molecular Pharmacology and Structural and Computational Biology.
IRB Barcelona has also an External Advisory Board, made up of leading scientists, which is responsible for assessing the activity and production of the groups, lines and programmes. This evaluation process, which is a permanent practice that reaches all levels and areas of work, follows criteria of maximum independence and non-interference, crucial elements that ensure the highest quality of assessment. In addition to the exciting scientific environment, the IRB provides experimental support to research groups through a set of Technology Platforms that include Mass Spectometry, NMR and Transcriptomics and Proteomics Facility. Technology Transfer is supported via the University of Barcelona Innovation Centre.
The Institute of Biomedical Research August Pi Sunyer (IDIBAPS) is associated to the University of Barcelona School of Medicine-Hospital Clinic and a leading research center in Europe. The over 350 researchers working at the Institute published during 2010 more than 850 articles in international journals. IDIBAPS researchers are supported by state-of-the-art scientific support platforms (e.g. genomics, proteomics, tumour bank, cytomics, etc.). IDIBAPS is funded from public agencies (Spanish and European) and private donors that for the period 2003-2007 provided over 162 million euros.
The¬†Group of Transcriptional Regulation of Gene Expression, also an ICREA affiliated group, was created in 2007 and investigates the molecular mechanisms regulating gene expression during cell differentiation (epithelial, muscle, hematopoetic) and cancer. The group is housed in a brand new building (Center for Biomedical Research Cellex), opened in February 2013.
The Institute of Advanced Chemistry of Catalonia (IQAC) is a research center devoted to chemistry and is part of CSIC. The Agencia Estatal Consejo Superior de Investigaciones Cient√≠ficas (CSIC) is the largest public multidisciplinary research organisation in Spain. The CSIC collaborates with: national and international universities, public R&D and technological organizations, SMEs, Trusts and other Institutions of a scientific/technical nature. The CSIC has 132 institutes, including 52 Joint Research Units with universities or other research institutions distributed throughout Spain and abroad.
IQAC has been created for performing research of excellence with focus on basic chemical sciences, but also addressed to solve specific problems of our society by using tools from the chemistry-biology interface, theoretical chemistry, chemical and biomolecular nanotechnology and sustainable chemistry. In particular, the identification of science fields ¬†where our expertise can make important contributions is systematically pursued with an special emphasis in multidisciplinary collaborative research.
The IQAC Institute is situated in Barcelona and is located in Pedralbes, an attractive residential area of Barcelona that contains numerous other University Faculties and research Centers. ¬†Situated just 20 minutes from city downtown and the airport, getting to the Institute by public transport is fast and convenient.
The Barcelona Science Park is a meeting point where university, business and society come together. Its objective is to boost innovation, particularly in the life sciences.
Founded by the University of Barcelona in 1997, it was the first science park in Spain and is an international point of reference today in the promotion of innovation, with more than 2,200 professionals working there.
The goals of the Barcelona Science Park are:
¬∑ To promote quality research with the support of a wide range of technologies
¬∑ To revitalise the relation between university and business
¬∑ To boost the creation of new companies and institutions
¬∑ To promote the science-society dialogue and scientific vocations
At present the park is home to 3 research institutes, more than 60 companies, an incubator for biotechnology companies, more than 70 research groups and a wide range of research support technology. In addition, it organises more than 120 activities for the promotion of scientific culture and new careers in science, in which close to 6,000 people participate each year.
The PCB provides a wide offer of technology services linked to biomedicine, nanobioengineering and pharmaceutical chemistry. Occupying a total of 5,000m¬≤, these technology platforms comprise state-of-the-art equipment and services, managed by highly experienced staff. In addition to offering services, the platforms also actively participate in research projects, platform networks and technology development projects
Projects to UPG candidates 2013 were offered by:
- Experimental Toxicology and Ecotoxicology Unit (UTOX) -¬†Website: www.pcb.ub.cat/ceretox
The Experimental Toxicology and Ecotoxicology Unit (UTOX) is a Unit of the Barcelona Science Park (PCB), the objective of which is, on the one hand, to serve as a support resource for UB groups, companies located in the PCB and other public or private research centers; and, on the other, to carry out its own research projects or projects in collaboration with other partners.¬†The unit is also part of the GRET (consolidated Toxicology Research Group) and the CERETOX (Toxicology Research Centre, TECNIO agent).
The research team is composed of PhDs, university graduates and technicians from several different origins and training (biologists, biochemists and veterinaries).
The UTOX is positioned as the Toxicology Platform of the PCB and as a toxicology research, innovation and services centre, serving both the public and the private sector, where the priority is to provide advice on, design and perform customized toxicology studies (based on the specific regulatory and quality needs and requirements in each case). The unit collaborates and works with numerous research groups from different national and international universities, entities or public administrations, participating in a large number of public research projects (CENIT, Singular and Strategic Projects, 7PM, etc.), and, at the same time, provides support to companies who wish to develop new products by means of the transfer of technology. The primary intervention sectors are: the pharmaceutical, food, cosmetic, chemistry, veterinary, health care material and environmental management sectors.
- Institute of Molecular Biology of Barcelona (IBMB) -¬†Website: http://www.ibmb.csic.es
The Institute of Molecular Biology of Barcelona (IBMB) is a CSIC (Spanish Scientific National Council) institute devoted to basic research in the fields of Molecular Genomics, Cellular Biology, Development, and Protein Structure, located at the Barcelona Scientific Park (PCB). IBMB is among the top CSIC BIO institutes in Spain.
- Institute for Bioengineering of Catalonia - IBEC - Website: www.ibecbarcelona.eu
The Fundaci√≥ Institut de Bioenginyeria de Catalunya (IBEC) is a research institute covering most bioengineering fields, from basic research to medical applications, aiming to act as an international reference in this field. In this sense, IBEC was created in order to further the development of multidisciplinary research of excellence in biomedical engineering and become the technological counterpart to hospitals, biomedical research centres and universities in the area. In addition, the IBEC has access to powerful technological facilities, including the Nanotechnology Platform, which offers services in nanofabrication, nanomanipulation, and nanocharacterization. Finally, we have support from the IBEC offices of fellowships, purchases and finances, human resources, project managers unit, events organization, travel and scientific communication.
- Leitat Technological Center -¬†Website: www.leitat.org
LEITAT is a Technological Center, recognized by the Ministry of Economy and Competitiveness, that aims to collaborate with companies and institutions by adding technological value both to products and processes, and focuses its activity on research, development and industrial innovation (R+D+2i). LEITAT, in its intensive collaboration with enterprises, institutions and entrepreneurs, generates assets and technological value knowledge.
The Faculty of Chemistry (Universitat de Barcelona) is situated on the University's Pedralbes campus. The construction of a new building at that location began in 1998 and was opened in 2006.
The Faculty of Chemistry offers extensive facilities, including amply equipped multimedia classrooms, computer rooms, numerous teaching and research laboratories, a physics and chemistry reference library, study rooms, lounge and dining room, bookshop, copy service, cafeteria, and so on, where more than 2,000 students take the different courses on offer.
The "Synthetic Methodology Applied to Bioactive Compounds" (SMBioCom) research group led by Prof. Jordi Garcia is located in the Department of Organic Chemistry in the Faculty of Chemistry and belongs to the Institut de Biomedicina de la Universitat de Barcelona (IBUB). Its activity encompasses both academic and applied projects and places an emphasis on the use of boron and palladium chemistry in the area of stereoselective methodology and the synthesis of natural and bioactive compounds. We are also involved in challenging projects at the borders with biochemistry (analogues of C75 as anti-obesity and type 2 diabetes drugs or anti-cancer agents) and inorganic chemistry (C-H activation). We currently have an ongoing consultancy contract with the pharmaceutical company Esteve Qu√≠mica SA, on the development of new synthetic approaches to drugs.
The University of Barcelona (UB) was founded in 1450. Today it boasts of a student body of 74,000 and a teaching staff of 4,150 members. The UB is structured in related areas of teaching, twenty university schools, 96 departments and 71 degree courses. Postgraduate and graduate school programmes are also offered, as well as a large number of continuing education courses. UB students have access to an extensive range of services. Ten thousand bachelor‚Äôs degrees and 400 PhDs are awarded each year. Nowadays the university has four campuses in different parts of the city.
The UB is the largest of the six universities of Barcelona and of the ten in Catalonia. The UB is ranked the first Spanish university, and the twenty third European institution, in scientific quality and productivity. The UB manages about 150 European projects per year, for an amount of about 19.3 million ‚ā¨. In addition, the UB has implemented a quality programme aiming fundamentally to design mid and long term strategies in order to evaluate and improve teaching and research in public higher education.
The University of Barcelona (UB) is the Spain‚Äôs leading research university, publishing more research than any other Spanish institution with the sole exception of CSIC, the national research council, according to the European Commission's Third European Report on Science and Technology Indicators.
The faculties and the Scientific and Technical Services (SCT) of the University of Barcelona who are offering the above work programmes are housed on the Pedralbes campus:http://www.ut.edu/mapes/campus_diagonal.htm
A wide range of projects are proposed every year to UPG candidates by many different laboratories and Institutes of the Faculty of Pharmacy.
The Faculty of Medicine and Health Sciences from Universitat Internacional de Catalunya is located in the Hospital General de Catalunya, in the city of Sant Cugat del Valles, very close to Barcelona. The Underground takes you from the Faculty and goes to the center of Barcelona in only 20 minutes. The Biomedicine Research Laboratory from the Faculty of Medicine and Health Sciences has all the infrastructures to do research in neuroscience and cell metabolism.
The word ‚Äúbiogune‚ÄĚ means a site for biosciences, which is precisely what CIC bioGUNE is: a place that attracts talented researchers from all over the world. It was first opened in January 2005, as a centre dedicated to biomedical research and it is committed to high quality research based on state-of-the-art equipment and tools.
There are several Technological Platforms and Research Units in the Centre. The Units share common space, technical equipment and scientific interests.
The Centre is now well equipped technically and most groups are well formed with a variety of scientists from different backgrounds, and many of them from abroad, providing an stimulating and energetic environment for the training and scientific development of young investigators. The weekly seminars are in English, as well as our Data and Journal Clubs, contributing to the international atmosphere.
CIC bioGUNE is located outside Bilbao, a pretty and dynamic city in Northern Spain. The centre is very well equipped technically and the groups include a variety of scientists from different backgrounds, several of them from abroad, providing an stimulating and energetic environment for the training and scientific development of young investigators. The weekly seminars are in English, as well as our Data and Journal Clubs, contributing to the international atmosphere.
The Babraham Institute is an independent charitable life sciences Institute, receiving strategic support from the Biotechnology and Biological Sciences Research Council (BBSRC). It carries out research and advanced training with relevance to the biomedical, biotechnological, pharmaceutical and healthcare communities. Located near Cambridge, the Institute undertakes international quality life sciences research to generate new knowledge of biological mechanisms underpinning ageing, development and the maintenance of health. The Institute‚Äôs research is focused on understanding the biological events that underlie the normal functions of cells and the implication of failure or abnormalities in these processes. Research focuses on signalling and genome regulation, particularly the interplay between the two and how epigenetic signals can influence important physiological adaptations during the lifespan of an organism. By determining how the body reacts to dietary and environmental stimuli and manages microbial and viral interactions, we aim to improve wellbeing and healthier ageing. (www.babraham.ac.uk)
Major breakthroughs have been made at the Institute, unraveling the complexities of cellular communication and providing insight into the physiological processes behind medical conditions like hypertension, cardiac arrhythmia and heart failure, cancer and bipolar disorders such as manic depressive illness. The Institute‚Äôs research effort underpins the overall healthcare responsibility of the BBSRC and aims to provide novel targets for the development of therapies and diagnostics of potential social and economic benefit. Babraham Bioscience Technologies Limited (BBT) the Institute‚Äôs wholly-owned trading subsidiary, manages all commercial activities on the Babraham Research Campus, including technology and knowledge exchange.
There are four Institute Strategic Programmes (ISPs) of research: The Signalling ISP, The Epigenetics ISP, The Nuclear Dynamics ISP and The Lymphocyte Signalling & Development ISP. There are currently 28 Group Leaders at the Institute, 5 or 6 within each ISP. However, there is considerable cross-talk across ISPs, sharing complementary approaches to address a common set of biological questions about ageing and lifelong health.
Internationally recognised as a research centre of excellence, with particular strengths in epigenetics and molecular signalling, the Institute is also an exemplar in the training of graduates and postdoctoral scientists. There are about 330 people working at the Institute; this includes around 120 research scientists, laboratory support staff, about 70 PhD students and many working visitors, coming from all over the world. However, there are also around 350 other scientists at the campus working in early-stage lifesciences start-up companies in our campus ‚ÄėBioincubator‚Äô. This diverse, international mix of interests and cultures produces a stimulating research environment.
Innova Biosciences Ltd is an expanding biotechnology company located at the Babraham Research Campus, in beautiful countryside close to the historic University City of Cambridge. Innova develops innovative research products for the academic, hospital, diagnostic and pharmaceutical sectors. The company is best known for its revolutionary Lightning-Link¬ģ conjugation technology, which greatly simplifies the production of labelled antibodies, and for its InnovaCoatTM gold nanoparticles.
The Babraham Research Campus is also the home of around 30 other biotechnology companies and the Babraham Institute, an independent charitable life sciences research Institute. Innova staff have access to all of the facilities on the Campus, which includes cafes, restaurants and a gymnasium. There is also an active sports and social club.
In all our placements you will have the opportunity to gain experience in our R&D, manufacturing and QC labs and learn a wide range of techniques.
For further information about Innova‚Äôs products and technologies and latest news see: http://www.innovabiosciences.com
Kymab is a biopharmaceutical company engaged in the discovery and development of human monoclonal antibody therapeutics. Despite the prevalence and importance of the monoclonal antibody class of drugs, the industry has been relying on in vitro and in vivo technologies to generate antibodies that are not optimal and do not adequately replicate the full potential of the human immune system. Kymab is creating a mouse-based antibody discovery technology, the Kymouse‚ĄĘ, with a superior repertoire of B-cell mediated immune response that is expected to lead to the discovery of highly potent therapeutic antibodies with excellent affinities and neutralizing capability.
Unilever is one of the world‚Äôs most successful consumer goods companies; dedicated to meeting the everyday needs of people everywhere. Our foods and home and personal care brands reach consumers in all corners of the globe helping people feel good, look good and get more out of life. In fact someone, somewhere, reaches for a Unilever product 150 million times a day.
Globally Unilever invests approximately 2.5% of its turnover in research and development each year, and is the UK‚Äôs fourth biggest investor. This investment is a measure of Unilever‚Äôs commitment to science and technology and the pivotal role that science and technology plays in Unilever‚Äôs competitive edge. Every product Unilever makes and sells results from the application of science. Unilever‚Äôs scientists enjoy the best of both worlds ‚Äď being at the cutting edge of technology and also seeing their innovations deliver practical results every day to the consumer.
Unilever R&D Port Sunlight is the leading site for research and development into the company‚Äôs home and personal care brands. Scientists work to combine understanding in areas such as material, physical, biological and process sciences with the best consumer insights to give innovative branded products ready to be sold on the world‚Äôs supermarket shelves. The global brands our scientists innovate for include Dove, Sunsilk, Axe, Cif, Omo, Mentadent and Comfort
Eli Lilly and Company Limited is the UK affiliate of major American pharmaceutical manufacturer, Eli Lilly and Company of Indianapolis. This affiliate is one of the UK's top pharmaceutical companies, with a research and development centre, a manufacturing site and a distribution centre which exports medicines to all parts of the world.
Lilly medicines treat schizophrenia, diabetes, cancer, osteoporosis, attention deficit hyperactivity disorder, erectile dysfunction, severe sepsis, depression, infections, bipolar disorder and many other diseases.
Eli Lilly research and development efforts constantly strive to address urgent, unmet medical needs and to replace more expensive and invasive medical treatments. As Eli Lilly pursue this goal we endeavour to reduce the cost of disease thereby creating significant value to health care providers and in turn benefits to patients.
Lilly employs more than 35,000 people world-wide and markets its products in more than 140 countries.
The UK has a proud history of medical discovery and the Lilly Research & Development facility at Erl Wood Manor, Windlesham, Surrey continues this tradition. The Lilly Research Centre founded in 1967 has served as a centre of excellence contributing to the development of much needed new medicines. The most recent breakthrough was in the discovery and development of an innovative and very successful treatment for schizophrenia. This medicine is already a huge success for patients across the world. More recently this site won Lilly the "Queen's Award for Innovation" for the discovery and commercialisation of Zyprexa¬ģ.
Erl Wood in the UK has a strong focus on Neuroscience, and a proven ability to deliver important new medicines. Also at Erl Wood are the Clinical Pharmacology, Medical, Pharmacovigilence and Regulatory Affairs groups, which play an integral part in the discovery to launch process.